AR and prostate cancer: Our previous studies revealed that: (1) the silibinin scaffold exhibits higher selectivity towards AR-positive LNCaP prostate cancer cells than the 2,3-dehydrosilybin scaffold [14], (2) modifying the alcoholic 23-OH of 3,5,7,20-O-tetramethyl-2,3-dehydrosilybin or alcoholic 3-OH and/or 23-OH of 5,7,20-O-trimethylsilybin (5) led to good selectivity in suppressing LNCaP prostate cancer cell line [15,16].